GLP1R and Parkinson disease: Whereas GLP-1 and Exendin-4 have been demonstrated to enter the brain by simple diffusion58,59, few of the studies evaluating incretin mimetics in PD or other neurodegenerative preclinical models have evaluated pharmacokinetic measures in either plasma or brain.